1. Pink Sheet
  2. >>Geography
  3. >>Asia
  4. >>China

10 For 2020: Regulatory Trends To Watch In China

 
• By Brian Yang

2019 was the year that China approved the first new drug for Alzheimer's in nearly two decades and for the first US approval of an original cancer drug from China. While the simmering US trade war has been addressed by a phase one agreement to be signed, other uncertainties marked a year dominated by a large vaccine scandal and resulting bankruptcy, and increasing calls to include China in global clinical development plans.

Pink Sheet Perspectives 2019 to 2020
Intense Activity Marks China's Regulatory Year

With all the ebb and flow that there has been in China over the past year, the Pink Sheet picks the 10 most significant events that captured the major regulatory developments in the country’s highly dynamic and fluid biopharma sector in 2019 and provides a glimpse into what's coming in 2020. 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Asia